Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056472 · ClinicalTrials.gov registry record · Phase 3
Study of Pharmacotherapy of Psychotic Depression
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 3
- Development phase
- 259
- Enrollment target
NCT00056472 is a Phase 3 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 259 participants.
The verdict
NCT00056472, a Phase 3 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 259 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
Interventions
- OTHER placebo
- DRUG Olanzapine
- DRUG Sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2003-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056472
The ClinicalTrials.gov registry entry for NCT00056472 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00056472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056472 about?
NCT00056472 is a clinical study titled "Study of Pharmacotherapy of Psychotic Depression". This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
What is the current status of trial NCT00056472?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 259 participants. The study started on 2003-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00056472?
The interventions under investigation include: placebo (OTHER), Olanzapine (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00056472?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.